Findik, DuyguArslan, UgurBaykan, Mahmut2020-03-262020-03-2620070953-62051879-0828https://dx.doi.org/10.1016/j.ejim.2007.07.001https://hdl.handle.net/20.500.12395/21305Background: The aim of the present study was to determine hepatitis B virus DNA incidence, viral load, and mutations in blood donors with HBsAG and anti-HBs negative serology and antibodies to hepatitis B core antigen. Methods: Blood samples were collected from 1000 blood donors with HBsAg-negative test results. Anti-HBc total screening was performed using the ELISA method. HBsAg-negative/anti-HBc total-positive samples were tested for anti-HBs, anti-HBc IgM, HBeAg, and anti-HBc. Samples with isolated anti-HBc were determined for viral load of HBV DNA using real-time PCR. Results: Anti-HBc total was established as positive in 200 (20%) of the 1000 blood donors. While anti-HBs was negative in 59 (29.5%) of the 200anti-HBc-positive samples, it was found to be positive in 141 (70.5%) of them. All of the other hepatitis B markers were negative in all of the anti-HBs-negative samples. HBV DNA was not detected in the sera of the isolated anti-HBc-positive blood donors with real-time PCR. Conclusion: Although we could not detect HBV DNA in the sera of the isolated anti-HBc-positive blood donors, findings in the literature suggest that anti-HBc testing should be used in combination with HBsAg for the screening of blood donors to reduce risk. After that, the most appropriate algorithm to follow can be HBV DNA screening of donors. (c) 2007 European Federation of Internal Medicine. Published by Elsevier B.V All rights reserved.en10.1016/j.ejim.2007.07.001info:eu-repo/semantics/closedAccessblood donorsHBV DNAisolated anti-HBcArticle18857157518054706Q2WOS:000252465500003N/A